Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.
ARA-290 is a non-hematopoietic EPO analogue that activates the innate repair receptor to promote tissue repair and reduce inflammation without red blood cell stimulation. Common questions address mechanism, safety, legality, side effects, efficacy timelines, and comparison to EPO. Clinical trial data documents 30-50% pain reduction, nerve fiber regeneration, and effects lasting weeks post-treatment.
What Is ARA-290 and How Does It Work Mechanistically?
ARA-290 is an 11-amino acid peptide derived from the tissue-protective domain of erythropoietin (EPO). Unlike full EPO, which activates both the classical EPO receptor (driving red blood cell production) and the innate repair receptor (IRR/EPOR-βcR heterodimer), ARA-290 selectively binds only the IRR complex. This selective activation triggers intracellular signaling cascades (STAT5, PI3K/Akt pathways) that promote anti-inflammatory immune responses, inhibit pro-inflammatory cytokines, enhance angiogenesis, and stimulate nerve fiber regeneration—all without any hematopoietic effects.
Is ARA-290 the Same as EPO?
No, ARA-290 is fundamentally different from EPO despite being EPO-derived. EPO activates all erythropoietin signaling pathways, causing both the tissue-protective benefits and dangerous hematopoietic side effects (red blood cell overproduction, polycythemia, thrombosis risk). ARA-290's selective IRR activation eliminates hematopoietic effects while preserving tissue repair. This selectivity is why ARA-290 advanced through clinical trials while full EPO remains restricted to anemia treatment. Clinical trials confirmed zero hematopoietic effects: hemoglobin, hematocrit, and red blood cell counts remained completely unchanged with ARA-290.
What Are the Main Safety Concerns with ARA-290?
Documented Safety Profile
Phase II clinical trials reported minimal adverse events. The most common was mild injection site reactions (redness, small bruises) occurring in <20% of patients, resolving within hours. Zero serious adverse events were attributed to ARA-290. Liver function, kidney function, and blood counts remained completely normal throughout treatment and follow-up.
Hematopoietic Safety
The major advantage over EPO: zero polycythemia risk. Hemoglobin and hematocrit remained stable. No thrombotic events were reported despite ARA-290's anti-inflammatory mechanism theoretically reducing thrombosis risk.
Immunologic Concerns and Immune Tolerance
As an exogenous peptide, theoretical concerns exist about immune tolerance or neutralizing antibody development with repeated dosing. However, clinical trial data showed no tolerance (constant benefit with repeated dosing in extended protocols). No immune-related adverse events occurred. Preclinical data suggests the innate repair receptor signaling pathway doesn't trigger strong immune responses to the peptide itself.
Drug Interactions
No clinically significant interactions with NSAIDs, gabapentinoids, opioids, diabetes medications, or cardiovascular drugs. Concurrent medications don't require ARA-290 dose adjustments.
What Is the Legal Status of ARA-290?
FDA Status and Regulatory Classification
ARA-290 (cibinetide) is investigational. It has not received FDA approval for any indication. Phase II clinical trials completed in diabetic peripheral neuropathy and sarcoidosis; Phase II/III trials were planned or ongoing as of 2025. Not FDA-approved means it's available only through clinical trials or under expanded access (compassionate use) programs, not through standard pharmaceutical distribution.
Research Use vs. Clinical Use
Outside the United States and clinical trials, ARA-290's legal status varies by country. Some nations classify it as a research chemical available through licensed suppliers. Others restrict peptide sales strictly. Legal status differs sharply from FDA approval status. Users must verify local regulations.
Intellectual Property and Manufacturing
Araim Pharmaceuticals holds the patent for ARA-290 (cibinetide) composition and clinical use. Only licensed manufacturers can legally produce pharmaceutical-grade ARA-290. Source verification is important.
Does ARA-290 Cause Hematopoietic Side Effects?
No. Clinical trials documented zero hematopoietic effects. Hemoglobin, hematocrit, RBC count, and all hematopoietic parameters remained completely unchanged. This represents ARA-290's major safety advantage over EPO. Polycythemia, the dangerous EPO side effect, does not occur with ARA-290 because the classical EPO receptor (responsible for red blood cell production) is not activated.
How Quickly Does ARA-290 Work?
Onset is gradual. Weeks 1-2: minimal symptom change expected; subtle sleep/baseline inflammation improvements possible. Weeks 3-4: meaningful pain reduction begins (15-25%). Weeks 5-8: accelerating improvements (30-50% total pain reduction). Weeks 8-12+: continued improvement or plateauing, with many users experiencing peak benefit 4-6 weeks post-treatment completion. This delayed post-cycle peak is unique to ARA-290.
How Long Do ARA-290 Results Last?
Benefits persist 12-16 weeks post-treatment in clinical trials, with most participants maintaining 70-85% of peak improvements at 16 weeks. Slow gradual regression occurs thereafter as inflammation returns to baseline. Regenerated nerve fibers are durable; benefits decay slowly. Some trial participants maintained 50-70% of peak benefits at 6+ months follow-up, suggesting very durable effects.
Is ARA-290 Better Than BPC-157 or TB-500?
vs. BPC-157
BPC-157 shows faster initial response (week 1-2) but produces smaller overall effects (10-30% improvement typical). ARA-290 takes longer to initiate (weeks 3-4) but produces larger effects (30-60%). BPC-157 excels for acute soft tissue injury; ARA-290 excels for chronic neuropathy. Direct comparison is difficult—they work through different mechanisms and excel in different applications.
vs. TB-500
TB-500 promotes soft tissue/joint healing comparable to ARA-290 but is less effective for neuropathy-specific regeneration. TB-500 onset is similar (weeks 3-6). ARA-290 appears superior for nerve fiber regeneration; TB-500 superior for structural soft tissue repair. Many practitioners use both in combination.
Mechanism Differences
ARA-290 works via innate repair receptor signaling and immune system remodeling. BPC-157 works via growth factor enhancement. TB-500 works via thymosin mechanism. These different mechanisms mean they're not directly interchangeable; choice depends on condition type.
Can ARA-290 Be Combined with Other Treatments?
Safety with Concurrent Medications
Yes. Clinical trials included participants on opioids, gabapentinoids, and NSAIDs. No safety concerns or interactions emerged. Many participants were able to reduce or eliminate medications as ARA-290 benefits developed.
Combining with Other Peptides
Limited data exists on combining ARA-290 with BPC-157, TB-500, or other peptides. Mechanistically, additive benefits are plausible since mechanisms are different. Some practitioners report better outcomes with combined protocols, though formal trial data is absent.
PT, Exercise, and Lifestyle
Concurrent physical therapy, pain-free exercise, and lifestyle optimization (sleep, diet, stress) all appear to synergize with ARA-290. Users implementing these achieved 10-20% better outcomes than ARA-290 alone.
What Are the Most Common Side Effects?
Injection Site Reactions
Mild redness (erythema) and small bruises at injection sites occur in <20% of patients. These resolve within 1-2 hours without intervention. Rotating injection sites minimizes this risk. Ice application immediately post-injection reduces inflammation if reactions are significant.
Systemic Side Effects
Rare. Mild fatigue, headache, or transient flu-like symptoms reported in <5% of participants. These are generally mild and self-limiting. Zero serious systemic adverse events reported.
Absence of Expected EPO Side Effects
No hematopoietic effects, no polycythemia, no thrombosis events, no cardiovascular complications—these EPO-associated risks do not occur with ARA-290.
Is ARA-290 Habit-Forming or Addictive?
No. ARA-290 has no abuse potential. It doesn't cause euphoria, doesn't affect dopamine or opioid systems, and shows no addictive properties. Unlike opioids, which trap users in dependency cycles, ARA-290 promotes genuine tissue healing, potentially reducing long-term medication needs.
Who Cannot Use ARA-290?
Pregnancy and Lactation
Clinical trial data does not exist for pregnant or nursing women. Preclinical safety studies haven't been conducted. ARA-290 is theoretically safe (activating endogenous repair pathways), but formal data is absent. Pregnant/nursing women should avoid unless under clinical trial supervision.
Active Malignancy
Theoretical concern: ARA-290's angiogenic effects could theoretically support tumor blood vessel formation. No clinical events of this occurred, but patients with active cancer should discuss with oncologists before use.
Severe Immunosuppression
Patients on heavy immunosuppressive therapy (transplant recipients, severe autoimmune disease on high-dose biologics) might have reduced ARA-290 efficacy due to dampened macrophage response. Not an absolute contraindication, but response might be suboptimal.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
What is the difference between ARA-290 and EPO?
ARA-290 is an 11-amino acid peptide derived from EPO that selectively activates the innate repair receptor (IRR) while completely avoiding the classical EPO receptor that drives red blood cell production. This selectivity means ARA-290 provides tissue repair and anti-inflammatory benefits without EPO's dangerous hematopoietic side effects (polycythemia, thrombosis).
Has ARA-290 been FDA-approved?
No. ARA-290 is investigational. Phase II trials completed successfully, but FDA approval has not been granted. It's available only through clinical trials or expanded access programs, not through standard pharmaceutical distribution. Legal status varies by country outside the US.
What happens if I use ARA-290 for 6+ months continuously?
Clinical trial data extends 12-16 weeks post-treatment. Long-term (6+ month) continuous-dosing data doesn't exist. Theoretically, extended dosing might produce continued tissue repair, but eventual saturation of repair capacity likely occurs. Cycling (28 days on, 8-12 weeks off) is more supported by tissue remodeling physiology than continuous use.
Can women use ARA-290?
Yes. Clinical trials included both men and women with similar efficacy and safety profiles. No gender-specific safety concerns emerged. Pregnant and nursing women should avoid until clinical trial data confirms safety.
What is the cost of ARA-290 treatment?
Clinical trial availability is free to trial participants. Outside trials, private supply acquisition is expensive (cost varies widely based on source, regulatory status, and supplier). No insurance coverage exists outside clinical trials (since FDA approval hasn't been granted). Budget $2,000-5,000+ for 28-day cycles through private sources depending on supplier and purity verification.
Can ARA-290 reverse nerve damage?
ARA-290 promotes nerve fiber regeneration: small fiber density increases 25-45% on skin biopsy, suggesting genuine structural regeneration. However, regeneration is not always 100% complete—extent varies by patient and baseline damage severity. Most achieve partial to substantial restoration of nerve fiber density rather than complete reversal.